2. Academic Validation
  3. Identification of Sinigrin as Active Compound of Rape Pollen for Treating Benign Prostatic Hyperplasia Through PI3K/AKT/mTOR Axis

Identification of Sinigrin as Active Compound of Rape Pollen for Treating Benign Prostatic Hyperplasia Through PI3K/AKT/mTOR Axis

  • Phytother Res. 2025 May 8. doi: 10.1002/ptr.8447.
Bingliang Chen 1 2,  Yingchao Wang 3,  Guoda Song 1,  Meicheng Liu 4,  Peng Lv 1,  Bin Yang 1,  Hui Zhuge 3,  Yu Tang 3 5,  Yi Wang 3 5,  Jianbiao Yao 6,  Jianfang Wang 6,  Jihong Liu 1,  Xiaming Liu 1
Affiliations

Affiliations

  • 1 Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • 2 Department of Urology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • 3 Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • 4 Second Clinical College, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • 5 Future Health Laboratory Innovation Center of Yangtze River Delta Zhejiang University, Jiaxing, China.
  • 6 Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine Pharmaceutical Technology, Hangzhou, China.
PMID: 40343383 DOI: 10.1002/ptr.8447
Abstract

Benign prostatic hyperplasia (BPH) is a common proliferative disease in older males. PuleanPian, containing rape pollen (RP), is a certified BPH medicine, but its main active compound and mechanism are unknown. This study aims to identify the main active compound of RP for the treatment of BPH. BPH rat models were induced with estradiol/testosterone (E2/T) and treated with RP or its alcohol extract (ALRP). RNA-seq and metabolomics were conducted, and RP compounds were identified via liquid chromatography-mass spectrometry (LC-MS). In vitro experiments used BPH-1 and RWPE-1 cells. E2/T induced BPH symptoms, alleviated by RP and ALRP treatment. RP possibly acts through phosphatidylinositol-3-kinase (PI3K)/Akt pathways, promoting Autophagy. LC-MS identified five main RP compounds, with sinigrin implicated in BPH treatment via the PI3K/Akt(Akt Serine/Threonine Kinase 1)/mammalian target of rapamycin (mTOR) axis. Sinigrin may be the active compound in RP for BPH treatment, acting through the PI3K/Akt/mTOR axis.

Keywords

LC–MS; benign prostatic hyperplasia; rape pollen; sinigrin.

Figures
Products